Vytorin: "No added benefit"

Kind’ve underlies the entire trouble with developing evidence based protocols. Often all the information isn’t on the table. For instance not having a good grip on why this drug should fail to lower the risk, when it lowers so many known contributors to that risk.

I should probably keep my comments to myself on any post concerning Zetia considering I used to refer to ezetimibe as “easy-te-me-be” from the day I learned about the drug second year all the way until I got corrected on my third year IM rotation.